TIL - Melanoma Cancer Treatment

Feb 22, 2025

By Andrew Wilson

A good friend of mine's melanoma has returned. Two years ago he went through the newest immunotherapy treatment and we were all excited that this chapter was behind us. Unfortunately it was not.

With the bad news of the cancer's return, we are also heartened by a recently FDA approved therapy, TIL (Tumor-Infiltrating Lymphocyte) and the program being let by Dr. Sylvia Lee at the Fred Hutchinson Cancer Center in Seattle.

Here is some more information on TIL therapy.

Tumor-Infiltrating Lymphocyte (TIL) therapy is an advanced form of immunotherapy designed to harness a patient’s own immune system to combat melanoma. This approach involves extracting TILs—immune cells that have naturally migrated into the tumor—from a patient’s tumor sample. These cells are then expanded and activated in a laboratory setting before being reintroduced into the patient’s bloodstream, where they target and attack cancer cells. To enhance the effectiveness of the infused TILs, patients often receive interleukin-2 (IL-2) therapy, a cytokine that promotes T-cell growth and activity. IL-2 can be administered systemically or directly into the tumor, depending on the treatment protocol.

Dr. Sylvia Lee, an oncologist at Fred Hutchinson Cancer Center, specializes in TIL therapy for melanoma and lung cancers. She leads the TIL Therapy Program at Fred Hutch, one of only four centers in the United States offering clinical trials in this area. Dr. Lee’s work focuses on extracting TILs from patients’ tumors, expanding them in the lab, and reinfusing them to bolster the body’s natural defenses against cancer. Her research aims to refine this process to improve patient outcomes and expand the applicability of TIL therapy to other cancer types.

Clinical studies have demonstrated that TIL therapy can be effective, particularly in patients with metastatic melanoma who have not responded to other treatments. Response rates in these heavily pretreated patients range from 30% to 50%, with some experiencing complete and long-lasting remissions. For instance, a study reported that among patients treated with TILs, 20% achieved a durable complete response.

However, TIL therapy is associated with significant side effects, primarily due to the IL-2 administration and the preparative regimens used to enhance TIL efficacy. Common side effects include flu-like symptoms, nausea, low blood pressure, and more severe complications such as vascular leak syndrome, which can lead to life-threatening conditions like pulmonary or brain edema. These adverse effects typically occur within the first two to three weeks post-treatment, with few long-term side effects observed.

In summary, TIL therapy combined with IL-2 offers a promising treatment avenue for patients with advanced melanoma, especially those who have exhausted other options. Under the guidance of experts like Dr. Sylvia Lee, ongoing research continues to optimize this therapy, aiming to enhance its efficacy while managing its associated risks.

Get the Free Trial to Try Memios

Start Your Free Trial

TIL - Melanoma Cancer Treatment

Stay Connected